9th Annual Biomarkers Congress

View Profile


Grant Support

Start year End year Title Source Position
1. 2013 HCMV Vaccine produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry NIAID PI
2. 2013 WT1 as a Biomarker to predict Relapse in Patients with Acute Leukemia and MDS NIH PI
3. 2013 IDO-silencing Salmonella therapy for the treatment of primary and metastatic PDAC NIH PI
4. 2012 2013 Manipulating the Gut Micro-Environment to Augment Tumor-Specific Immunity and Regression Caltech-COH Biomedical Initiative PI
5. 2012 2013 Clinical and Biological Roles of WT1-specific T cells in non-Hodgkin Lymphoma ThinkCure Foundation Co Investigator
6. 2012 2013 Salmonella therapy for primary and metastatic PDAC that functions by defeating immunosuppression Hirschberg Foundation PI
7. 2012 2013 Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems Nesvig Foundation PI
8. 2012 2013 HCMV Vaccine Produced from BAC-MVA that Blocks Epithelial and Fibroblast Entry Excellence Award PI
9. 2011 2013 A Phase I Study of an MVA Vaccine Targeting p53 in Cancer Institutional Funding PI
10. 2012 Development of p53-MVA for advanced Pancreas Cancer Susan E. Riley Foundation PI
11. 2012 Evaluation of safety and correlative immunogenicity studies of a CMV peptide vaccine co-injected with PF03512676 adjuvant in recipients of allogeneic HCT NIH Co Investigator
12. 2012 A Phase I Study of a p53 MVA Vaccine for Advanced Colon, Gastric and Pancreatic Cancer Phase I Program Co Investigator
13. 2012 Control of CMV infection after HCT using an attenuated MVA-based CMV vaccine NCI PI
14. 2009 2012 Hematopoietic Cell Transplantation for Hematologic Malignancies NIH-NCI PI
15. 2006 2012 Hematopoietic Cell Transplantation for Hematologic Malignancy NIH-NCI PI
16. 2011 Optimizing shRNA Approaches for Control of Experimental Murine Lymphoma using Salmonella Delivery Systems Nesvig Foundation PI
17. 2011 Vaccinia Virus Vector (Modified Vaccinia Ankara) Expressing p53 Gene, Coley Pharmaceutical Group, Inc Co Investigator
18. 2009 2011 WT1 as a Universal Therapeutic Vaccine Target for Hematologic Malignancy and Solid Tumors ThinkCure Foundation PI
19. 2009 2011 IL-10 & PD-1 Modulation to Reduce CMV Disease Incidence in Solid Organ Recipients NIH Consultant
20. 2009 2011 Hematopoietic Cell Transplantation for Hematologic Malignancies NIH-NCI PI
21. 2007 2011 Hematopoietic Cell Transplantation for Hematologic Malignancies NIH-NCI PI
22. 2007 2011 Recombinant Modified Vaccinia Ankara Expressing CMV Antigens for use in Stem Cell Transplantation for Hematologic Malignancy NCI-RAID PI
23. 2004 2011 Peptide Vaccine to Prevent CMV Disease after HSCT NCI PI
24. 2010 Evaluation of Protective CMV Vaccines in Rhesus Macaques NIAID PI
25. 2009 2010 Clinical Oncology Research Career Development Program NIH Mentor
26. 2008 2010 Rhesus CMV Infection of Immunosuppressed CMV-naïve Rhesus Macaques NCRR PI
27. 2008 2010 GLP Production of CMV-MVA as Seed Stock for GMP Production NCI-SAIC-Frederick PI
28. 2007 2009 Molecular Diagnosis of Defective Memory Differentiation in Tumor-Specific T Cells NIH NCI Co Investigator
29. 2005 2009 An MVA Vaccine Targeting p53 in Breast Cancer FAMRI Consultant
30. 2005 2009 Clinical Evaluation of a Poxvirus Vaccine Targeting p53 NIH NCI Co Investigator
31. 2005 2008 CpG DNA:Epitope Fusion Peptide Conjugates as HIV Vaccines NIH-NIAID PI
32. 2004 2008 Evaluation New Targets of CMV Cellular Immunity NIH Co Investigator
33. 2005 2007 A Modified Vaccinia Virus Ankara Targeting p53 in Breast Cancer NCI-RAID Consultant
34. 2005 2007 GLP Production of p53-MVA as Seed Stock for GMP Production NCI-SAIC-Frederick PI
35. 2004 2007 HLA Tetramer-Guided Analysis of CMV Immunity after HCT LLS Co Investigator
36. 2006 CMV Fusion Peptide (PADRE T-cell helper epitope and Tetanus T-cell helper epitope; synthetic; Bachem California) Vaccine with and without Oligodeoxynucleotide Immunomodulator Coley Pharmaceutical Group, Inc Investigator
37. 2004 2006 Cellular Immunity to BK Virus NIH-NCI Co Investigator
38. 2002 2006 HCV and Progression of HIV and HAART Response in Women NIH Co Investigator
39. 1998 2006 Development of a GMP-Manufacturing Strategy and Acquisition of Clinical-Grade Quantities of a Lipopeptide Vaccine with Activity Against Cytomegalovirus NCI-RAID PI
40. 2004 2005 Design of an in vivo Assay to Measure the Potency of the PADRE-CMV and Tetanus-CMV Peptides NCI-SAIC-Frederick PI
41. 2003 2005 Early Therapeutics Development with Phase II Emphasis NIH-NCI Co Investigator
42. 2000 2005 Acquisition of Immunity to CMV NCI PI
43. 2002 2004 Ubiquitin Targeting to Enhance Immune Response to HIV Antigen University of California AIDS Research Program PI
44. 2001 2004 HLA Tetramer-Guided Analysis of CMV Immunity After BMT The Leukemia and Lymphoma Society Consultant
45. 1998 2004 “Lipopeptide Vaccine to Prevent HCMV Infection after BMT NCI PI
46. 1998 2003 Vaccination for CMV in AIDS Patients Undergoing HAART NIH PI
47. 2000 2002 Preclinical Evaluation of Mono- and dilapidated Vaccines for Activity Against Cytomegalovirus NCI PI
48. 1998 2002 Lipopeptide Vaccination Against AIDS in Patients Undergoing HAART NIH PI
49. 1997 2002 Therapeutic Vaccine to Limit CMV Infection After BMT Leukemia Society of America PI
50. 1997 2002 p53 Directed Immunotherapy of Breast Cancer NCI Consultant
51. 1999 2000 Vaccination for CMV in AIDS Patients Undergoing HAART NIH PI
52. 1995 2000 Acquisition of Immunity to CMV NCI PI
53. 1995 2000 Allogeneic Bone Marrow Transplantation for Hematologic Malignancy NCI PI
54. 1992 2000 Clinical Oncology Research Career Development Program NIH PI
55. 1998 Purchase of Flow Cytometer H.N. and Frances C. Berger Foundation PI
56. 1992 1995 Identification of T Cell Receptor Variable Gene Segments Associated with the Clinical Course of GVHD in Recipients of Allogeneic Bone Marrow Transplants NCI PI
57. 1992 1995 The Antigen Specific Immune Responses to HCMV NCI NCI Co PI
58. 1990 1994 IFN-γ Expression in Leukemic and Activated T cells National Cancer Institute Co Investigator
59. 1991 1992 Clinical Applications of a Soluble Antigen-Specific T Cell Receptor: A Reagent for Studying Auto-immunity Rheumatic Disease Research Foundation PI


4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.